Active Ingredient(s): Eribulin Mesylate
FDA Approved: * November 15, 2010
Pharm Company: * EISAI INC
Category: Cancer

Eribulin, sold under the brand name Halaven, is an anticancer medication used to treat breast cancer and liposarcoma.[2][4] The most common side effects include fatigue, nausea, hair loss (alopecia), constipation, certain nerve damage causing weakness or numbness in the hands and feet (peripheral neuropathy), abdominal pain and fever (pyrexia).[7] Eribulin may also cause low levels of infection-fighting white blood cells (neutropenia) or decreas... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Halaven .5 mg/ml Intravenous Injection
NDC: 43624-002
Bsp Pharmaceuticals Spa
Halaven .5 mg/ml Intravenous Injection
NDC: 62856-389
Eisai Inc.